DREAMS is committed to achieving a 40 percent reduction in new HIV/AIDS infections among adolescent girls and young women in the highest-burden countries by the end of 2017.
Despite considerable progress in the overall global HIV/AIDS response, gender and age disparities in high-HIV burden sub-Saharan African countries remain almost unchanged. Girls and young women account for 74 percent of new HIV infections among adolescents in sub-Saharan Africa. The 10 DREAMS countries (Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe) account for more than half of all the new HIV infections that occurred among adolescent girls and young women globally in 2015.
Many adolescent girls and young women lack a full range of opportunities and are too often devalued because of gender bias, leading them to be seen as unworthy of investment or protection. Social isolation, economic disadvantage, discriminatory cultural norms, orphanhood, gender-based violence, and school drop-out all contribute to girls' vulnerability to HIV.
DREAMS is about multiple solutions surrounding one problem. With support from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences, and ViiV Healthcare, DREAMS is delivering a core package that combines evidence-based approaches that go beyond the health sector, addressing the structural drivers that directly and indirectly increase girls' HIV risk, including poverty, gender inequality, sexual violence, and a lack of education.
DREAMS is focused on implementing evidence-informed and innovative approaches to empower adolescent girls and women in districts of 10 sub-Saharan African that have the highest burden of HIV infection.
The DREAMS Core Package includes evidence-informed approaches to address the structural drivers that directly or indirectly increase girls' HIV risk, including poverty, gender inequality, sexual violence, and lack of education. These approaches are being implemented in four key areas to empower girls and young women, reduce the risk of sex partners, strengthen families, and mobilize communities for change.
Launched by the United States in 2014, DREAMS is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Girl Effect, the Bill & Melinda Gates Foundation, Johnson & Johnson, ViiV Healthcare, and Gilead Sciences.
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) is the U.S. government’s initiative to help save the lives of those living with and affected by HIV/AIDS around the world. The U.S. Department of State leads, coordinates, and funds PEPFAR, investing over $70 billion dollars in the global HIV/AIDS response to date. PEPFAR’s investment, the largest commitment by any nation to combat a single disease in history, also helps to advance global progress toward other key health and development goals.
HIV is one of the leading priorities of the Bill & Melinda Gates Foundation. The goal of the foundation’s HIV initiative is to support efforts to reduce the global incidence of HIV significantly and sustainably and to help people infected with HIV lead long, healthy, and productive lives. The primary focus of the foundation’s efforts is in the poorest hyper-endemic countries of Sub-Saharan Africa where their resources can have the greatest impact. To date, the foundation has committed more than US$2.5 billion in HIV grants to organizations around the world.
In 2008 the NIKE Foundation, in collaboration with NoVo Foundation, United Nations Foundation, and other partners, launched the Girl Effect movement. With the support of over 150 partners in 90 countries the Girl Effect movement positively impacted the lives of millions of girls and influenced investment in them. Girl Effect is now a new organization that drives forward the ambition to give girls access to the critical assets they need to achieve their full potential. The organization works to break the cycle of intergenerational poverty by harnessing media in innovative ways and building social networks that develop girls' positive perceptions of themselves and shift how others see and value them.
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. Johnson & Johnson has a long-standing legacy of commitment and partnership to improve global public health for individuals, families and communities worldwide. Through its new global public health organization, the company aims to deliver integrated evidence-based solutions to address comprehensive health needs and deliver meaningful and enduring impact in three core focus areas: HIV, maternal and child health, and extreme-multi-drug resistant (XDR)- and MDR-TB.
ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV. The company offers a broad portfolio of antiretroviral medicines to support patients with diverse needs and an industry-leading pipeline of potential treatment options. Through its Positive Action programs, ViiV Healthcare also focuses on developing sustainable community responses to prevent the further spread of HIV and support people living with HIV through over 350 active partnerships across the world.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. They strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of marketed products includes complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.